We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
-8.12%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$116M
AUM Growth
-$19.4M
(-14%)
Cap. Flow
-$5.91M
Cap. Flow
% of AUM
-5.09%
Top 10 Holdings %
Top 10 Hldgs %
74.92%
Holding
39
New
9
Increased
9
Reduced
5
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$6.7M |
| 2 |
CMRX
Chimerix, Inc.
CMRX
|
+$5.04M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$4.69M |
| 4 |
INSY
Insys Therapeutics, Inc.
INSY
|
+$2.77M |
| 5 |
MZOR
Mazor Robotics Ltd.
MZOR
|
+$2.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Omeros
OMER
|
+$6.04M |
| 2 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$4.49M |
| 3 |
NVDQ
Novadaq Technologies Inc.
NVDQ
|
+$4.12M |
| 4 |
Standard BioTools
LAB
|
+$3.97M |
| 5 |
EPZM
Epizyme, Inc
EPZM
|
+$2.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.33% |
| 2 | Miscellaneous | 16.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KIPS
26
DELISTED
KIPS BAY MEDICAL INC
KIPS
| $355K | 0.31% |
772,031
-5,500
| -0.7% | -$2.94K |
|
27
Prothena Corp
PRTA
$467M
| $295K | 0.25% |
+13,104
| New | +$328K |
|
28
Geron
GERN
$983M
| – | – |
-1,163,800
| Closed | -$2.3M |
|
|
29
Standard BioTools
LAB
$256M
| – | – |
-90,000
| Closed | -$3.97M |
|
30
Ligand Pharmaceuticals
LGND
$5.67B
| – | – |
-56,105
| Closed | -$2.35M |
|
31
MacroGenics
MGNX
$260M
| – | – |
-30,000
| Closed | -$838K |
|
32
Nuwellis
NUWE
$3.14M
| – | – |
0
| – | -$350K |
|
|
33
Omeros
OMER
$1.39B
| – | – |
-500,100
| Closed | -$6.04M |
|
|
EPZM
34
DELISTED
Epizyme, Inc
EPZM
| – | – |
-115,500
| Closed | -$2.63M |
|
|
FLXN
35
DELISTED
Flexion Therapeutics, Inc.
FLXN
| – | – |
-135,500
| Closed | -$2.23M |
|
|
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-305,000
| Closed | -$1.43M |
|
|
NVDQ
37
DELISTED
Novadaq Technologies Inc.
NVDQ
| – | – |
-167,600
| Closed | -$4.12M |
|
|
AFFX
38
DELISTED
Affymetrix Inc
AFFX
| – | – |
-100,000
| Closed | -$713K |
|
|
NPSP
39
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| – | – |
-150,000
| Closed | -$4.49M |
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q2 2014 Portfolio in Review
As of Q2 2014, Opaleye Management held 39 positions worth $116M, down 14% from $135M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Opaleye Management withdrew a net $5.91M in Q2 2014, closing 11 positions and reducing 5 holdings. Its most notable exit was Omeros, an estimated $6.04M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 80% a quarter earlier, followed by Miscellaneous.
Against the trend, Opaleye Management opened a new position in Clovis Oncology, Inc. worth $5.37M.
- Opaleye Management's largest Q2 2014 buy was Clovis Oncology, Inc.: 130,000 shares worth $5.37M.
- Opaleye Management added most to Chimerix, Inc. in Q2 2014, an estimated $5.04M increase.
- Opaleye Management's biggest Q2 2014 reduction was BioLineRX, cutting an estimated $1.67M.
- Opaleye Management fully exited Omeros in Q2 2014, selling an estimated $6.04M.
- Opaleye Management's ten largest holdings make up 75% of its $116M portfolio in Q2 2014.
- Opaleye Management opened 9 new positions and closed 11 in Q2 2014.
- Opaleye Management's portfolio value fell 14% quarter-over-quarter to $116M.
Based on Opaleye Management's 13F filing for Q2 2014, filed 14 Aug 2014.